Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 trial of LB-001

Trial Profile

Phase 1/2 trial of LB-001

Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2018

At a glance

  • Drugs LB 001 (Primary)
  • Indications Methylmalonic acidaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Dec 2018 New trial record
    • 03 Dec 2018 According to a LogicBio Therapeutics media release, company expects to file an IND for LB-001 in late-2019 and initiate this study shortly thereafter.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top